Fe Pharmaceuticals Closes SEED Investment and Names Robert Klein to the Board of Directors

Redwood City, California--(Newsfile Corp. - April 25, 2023) - Fe Pharmaceuticals has raised a SEED investment to continue developing DIBI, a non-toxic, iron-binding copolymer, as a potent, broad-spectrum, antimicrobial agent active against bacterial and fungal infections, including drug-resistant organisms and as a potential anti-inflammatory and cancer therapy.

To view the full announcement, including downloadable images, bios, and more, click here^[1].

Key Takeaways:

• Each year in the U.S. 2.8 million people are infected with antibiotic-resistant germs, and at least 35,000 die.
• DIBI is an iron-binding co-polymer that has shown proof-of-concept in a variety of infectious and inflammatory disease models with 27 peer-reviewed publications.
• Rob Klein, who managed reauthorization of CIRM through the $5.5 billion California Prop 14 bond initiative, joins the Board to raise awareness of this therapeutic approach.

Click image above to view full announcement.

About DIBI

DIBI is a non-toxic, iron-binding co-polymer with potent, broad-spectrum, antimicrobial activity against fungal and bacterial infections, including those caused by drug-resistant organisms. DIBI exploits the absolute requirement of pathogens for iron to grow and reproduce. DIBI scavenges only the circulating iron required for infections and not the iron inside host cells. DIBI is non-toxic, removes iron in a manner pathogens cannot become resistant to, is very broad spectrum and very potent, with sub-uM MICs (minimum inhibitory concentrations) against even drug-resistant pathogens like Methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. In multiple peer-reviewed studies using animal models of infection, including of the ear, skin, lung, and systemic, it was effective against bacterial and fungal species, with synergistic benefits when administered with conventional anti-infective agents. In animal models of sepsis, DIBI also down-regulated excess cytokine release and promoted survival, acting synergistically with antibiotics. Iron sequestration has applications in other diseases, and in published cancer research, DIBI inhibits cancer cell growth and acts as a strong sensitizer to conventional chemotherapy. 

About Fe Pharmaceuticals

Fe Pharmaceuticals (Canada) is a Nova Scotia, Canada company focused on medical indications related to iron availability, including infectious and inflammatory diseases and cancer. Fe Pharmaceuticals is a US subsidiary located in the San Francisco Bay area. Fe's lead product candidate DIBI fits the ideal product profile for an anti-pathogen agent and is currently in preclinical development.

Website: https://fepharm.com^[2]LinkedIn: https://www.linkedin.com/company/fe-pharmaceuticals/^[3]Facebook: https://www.facebook.com/FePharm^[4]Twitter: @ChelationPrtnrs; https://twitter.com/ChelationPrtnrs^[5]

Contacts:

Michael J. Weickert650-218-1840mweickert@fepharm.com^[6]

Source: Fe Pharma^[7]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/163693^[8]

References

1. ^{^} click here (api.newsfilecorp.com)
2. ^{^} https://fepharm.com (api.newsfilecorp.com)
3. ^{^} https://www.linkedin.com/company/fe-pharmaceuticals/ (api.newsfilecorp.com)
4. ^{^} https://www.facebook.com/FePharm (api.newsfilecorp.com)
5. ^{^} https://twitter.com/ChelationPrtnrs (api.newsfilecorp.com)
6. ^{^} mweickert@fepharm.com (www.newsfilecorp.com)
7. ^{^} Fe Pharma (api.newsfilecorp.com)
8. ^{^} https://www.newsfilecorp.com/release/163693 (api.newsfilecorp.com)